The advent of targeted anticancer therapies over the past few decades has reinvigorated the
field of cancer therapeutics, with the promise of increased cancer cure rates accompanied …

Irinotecan (CPT11), a broad-spectrum cytotoxic anticancer agent, induces a series of toxic
side-effects. The most conspicuous side-effect is gastrointestinal mucositis, including …

Background: Dihydropyrimidine dehydrogenase (DPD) catabolises∼ 85% of the
administered dose of fluoropyrimidines. Functional DPYD gene variants cause …

Maslinic acid (MA), a natural triterpenoid abundant in olives, has a variety of bioactivities.
However, its effects and mechanisms on colorectal cancer (CRC) still need to be explored …

Abstract The phosphoinositide 3-kinase (PI3K) pathway, one of the most commonly
activated signaling pathways in human cancers, plays a crucial role in the regulation of cell …

Scope: Lunasin is an arginine‐glycine‐aspartic acid (RGD) cancer preventive peptide. The
objective was to evaluate the potential of lunasin to induce apoptosis in human colon cancer …

Background Oxaliplatin is an integral component of colorectal cancer treatment, but its use is
limited by neurotoxicity. The Combined Oxaliplatin Neurotoxicity Prevention Trial …

The development of effective therapies for the prevention of colorectal cancer (CRC) liver
metastasis is of great importance. Recently, chitosan (CS) nanoparticles have been utilized …

Circadian timing of anticancer medications has improved treatment tolerability and efficacy
several fold, yet with intersubject variability. Using three C57BL/6-based mouse strains of …

Doxorubicin (Dox) is known for its potential to deliver desirable anticancer effects against
various types of cancer including colorectal cancer. However, the adverse effects are …